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Vascular endothelial cells, which form the interface between blood and solid tissues,
interact with circulating leukocytes, including T lymphocytes, monocytes, and poly-
morphs and can mediate antigen presentation. Some of the factors involved in en-
dothelial cell-leukocyte interaction or its regulation have been elucidated. These in-
clude ICAM-1 and the leukocyte adhesion family ofmolecules (1). The lymphokines
IL-1, TNF, and IFN-y are known to stimulate differentially the interaction of var-
ious leukocyte types with endothelial cells in culture (2, 3). The involvement of the
complement system and its receptors in mediating contact of other cell types with
endothelia has not been widely investigated, although endothelial cells are known
to express decay-accelerating factor (DAF) (4) and a Clq-binding activity (5). In
this study, we present evidence that endothelial cells contain mRNA for comple-
ment factors H, I, and B, and that specific mRNA levels and factor H secretion
are profoundly altered by IFN-y.
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Materials and Methods
BriefDefinitive Report
Endothelial Cells.
￿
Human umbilical vein endothelial cells (HUVEC) isolated according
to Jaffe et al. (6) were established by Professor N. Kefalides at the Sir William Dunn School
of Pathology, Oxford. Cells were grown in a-MEM with 10oyo FCS, 20 gg/ml endothelial cell
growth supplement (No. E9005; Sigma Chemical Co., St. Louis, MO), 2 mM glutamine,
90 jig/ml heparin (Sigma Chemical Co.), 2.5 vg/ml fungizone, 50 pg/ml penicillin, 50 gg/ml
streptomycin. Cell culture reagents were from Gibco Laboratories, Paisley, Scotland or Flow
Laboratories, Irvine, Scotland. Cells were grown to confluence in 75-cm2 flasks coated with
1 % gelatin. Confluent cells were subcultured using trypsin-EDrFA, and cells in the fifth through
tenth passage were used for experimental work. Cells were incubated with IFN-'Y (100 IU/ml),
IL-1 (100 IU/ml), LPS (10 gg/ml; from Salmonella abortus equi; Sigma Chemical Co.) or TNF
(100 IU/ml) for 2 or 3 d before harvest. IFN-y and TNF were recombinant human proteins
isolated from Escherichia coli produced by Genentech Inc. (San Francisco, CA) and supplied
by Boehringer Ingelheim, Vienna, Austria. IL-1 was human rIL-la purified from E. coli,
a gift from Dr. P. T. Lodemico, Hoffman-La Roche Inc., Nutley, NJ.
Solubilization ofCells.
￿
Confluent HUVEC were solubilized by either of two methods. For
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Western blotting and after biosynthetic labeling, cells were detached from the flask using
a rubber "policeman" in the presence of lysis buffer (10mM sodium phosphate, pH 7 .5, con-
taining 0.15mM CaC12 , 0.5 MM MgC12 , 1 ° Jo vol/vol NP-40, 100 ttg/ml soybean trypsin in-
hibitor (Sigma Chemical Co.), 10 mM iodoacetamide (Sigma Chemical Co.), 2.5 mM di-
isopropylfluorophosphate (Sigma Chemical Co.), 2.5 gg/ml pepstatin A (Sigma Chemical
Co.) and 20 wM 1,10 phenanthrolene . The mixture was incubated 30 min at 0 °C, centrifuged
(20 min, 13,000g), and the supernatant was frozen at -70°C . For Northern blot experiments
cells were collected by trypsinization, washed four times with PBS at 4°C, then RNA was
prepared as before (7) . The procedure included a CsCl gradient step to separate RNA from
protein .
Proteins andAffinity Reagents .
￿
Factor H was isolated as before (7) . Polyclonal rabbit anti-factor
H antibodies bound to CNBr-activated Sepharose were used in immunoadsorption .
cDNA Probes and Northern Blotting .
￿
Northern blotting was done as before (8) . RNA was
denatured using formamide and formaldehyde, and electrophoresis was done on gels con-
taining formaldehyde . cDNA probes used were as follows : B38-1, encoding the NH2 terminal
one-third offactor H (7) ; a C4bp probe (8) ; a full-length factor I-specific probe (9), kindly
provided by Dr. C . Catterall, Celltech Ltd ., Slough, England ; the factor B probe pFB-3b
(10) ; the CR3-0 chain probe, J-9 (11), and the full-length Clq-B chain probe (12), provided
respectively by Drs . R . D. Campbell, S. -K . A . Law and K . B . M . Reid, MRC Immuno-
chemistry Unit, Oxford, England . Probes were labeled with 32P by nick translation or
random priming. Human liver mRNA, prepared as described (7), was used as a positive
control in Northern blotting . Autoradiographs ofblots were analyzed using anLKB Produkter
(Bromma, Sweden) laser densitometer.
SDS-PAGE and Western Blotting.
￿
Samples of endothelial cell culture supernatants and solu-
bilized cell extracts were analyzed on 7.5% SDS-polyacrylamide gels and blotted onto nitrocel-
lulose (Hybond C ; Amersham International, Amersham, UK). Blots were developed using
rabbit polyclonal anti-factor H and alkaline phosphatase-conjugated second antibodies .
Biosynthetic Labeling of Cells and Immunoadsorption.
￿
HUVEC were grown to confluence,
washed with cysteine-free medium, and incubated (30 min, 37°C) in the same medium . L-
[ 35S]cysteine (sp act, 120 mCi/mmol ; Amersham International) was added (250 pCi/75-cm 2
flask), and cultivation was continued for 12 h . Culture supernatants and cells were collected
as described above, the cells were lysed, and culture supernatant (5 ml) or soluble cell extracts
(5 ml) were incubated (16 h, 4°C) with 0.7 ml (packed volume) Sepharose-anti-factor H .
The affinity resin was washed, and bound material was eluted and analyzed by SDS-PAGE
as described previously (13) . Cysteine-free medium was made using an MEM-Selectamine
Kit (Gibco Laboratories) and dialyzed FCS.
Results and Discussion
Detection of FactorH and FactorH mRNA .
￿
Northern blotting of endothelial cell
total RNA (Fig. 1) with the factor H probe B38-1 showed that the characteristic
4.3-kb and 1.8-kb factorHmRNA species were detectable inHUVEC grown under
standard conditions (Fig . 1, lane b) . The presence of IFN-y in the medium caused
a six- to sevenfold increase (as judged by densitometry of the autoradiograph) in
both mRNA species (Fig . 1, lane c) . The quantity of the H-specific 4.3-kbmRNA
was high in IFN-y-stimulated cells, being N20-25% of the level found in an equal
weight of total livermRNA . In contrast, factorHmRNA was not detectable in 20
ltg of U937 cell poly(A)+ mRNA, although these cells do express factor H (13) .
The 4.3- and 1.8-kbmRNA species are ofsimilar abundance in liver samples (Fig.
l, lane a ; reference 7), whereas inHUVEC, the smaller mRNA is consistently present
at only 10-20% of the level of the 4.3-kb species . The 1.8-kbmRNA is thought to
arise by alternative splicing and encodes the first seven repeat units (ti420 amino
acids) of factor H, plus a short, unique COOH-terminal sequence (7) . The differ-RIPOCHE ET AL .
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FIGURE 1 .
￿
Expression of factor HbyHUVEC : Northern blot anal-
yses . Total RNA was run under denaturing conditions and blotted
onto nitrocellulose . The filter was probed using the factor H probe
B38-1 . (Lane a) Total RNA (4 pg) from human liver ; (lane b) total
RNA(20 pg) from controlHUVEC; (lane c) total RNA(20 pg) from
IFN-y-stimulated (100 IU/ml, 3 d)HUVEC . The 5.3-5.5-kb mRNA
seen in liverRNA is thought to be aconformational artefact (7) . Kilo-
base markers shown .
ence in relative proportion of the twomRNAs between liver andHUVEC indicates
a tissue-specific control mechanism, possibly influencing alternative splicing .
A third type of factor H mRNA (1 .2-1.5 kb) occurs in liver (7) but is detectable
only with 3' cDNA probes, and was not investigated here .
Incubation ofHUVEC with TNF did not affect factor H mRNA levels, while
IL-1 and LPS had a small suppressive effect (10-50% decrease in the level of both
H mRNA species; results not shown) . Cells incubated with both IL-1 (100 IU/ml)
andIFN-y (100 IU/ml) had similarHmRNA levels to control cells, which indicates
that IL-1 suppresses the effect of IFN-y .
The synthesis and secretion of factor H by HUVEC was confirmed by biosyn-
thetic labeling with [3sS]cysteine followed by immunoadsorption with solid-phase
anti-factorH antibodies (Fig . 2A) . Radiolabeled protein comigrating on SDS-PAGE
with factorH in both reducingandnonreducing conditions wasobserved . Thequantity
of labeled protein detectable was increased when cells were incubated with [35S]cys-
teine in the presence of 100 IU/ml IFN-y . Factor H was also detectable in uncon-
centrated culture supernatants by Western blotting (Fig. 2 B), and again the quan-
tity detectable was greater in supernatants from IFN-y-treated cells . Factor H was
detectable in detergent-solubilized cell extracts by both biosynthetic labeling and
Western blotting (not shown), but it was not established whether this was cell sur-
face-associated factor H (13), or an internal pool destined for export.
Detection ofmRNA for Other Complement Components.
￿
Since factorH mRNA was
readily detectable, and C3 secretion by HUVEC has been reported by others (14),
mRNA forotheralternativepathway-associated proteins was sought . Factor ImRNA
was detectable inHUVEC grownunder standard conditions (Fig . 3A) . IFN-y treat-
ment increased the factor I mRNA level >10-fold . Factor B mRNA was detected
in IFN-y-treated HUVEC, but not in unstimulated cells (Fig. 3 B) . The level of
B mRNA in IFN-y-stimulated cells was low, relative to the liver control (1-1.5% of
the B mRNA present in an equal weight of total livermRNA). mRNA for Clq,
C4bp, and the a chain ofCR3, p150, 95, and LFA-1 was not detected in either un-
stimulated or IFN-y-treated cells . The presence ofmRNA for H, I, and B, together
with demonstration ofC3 secretion (14), implies that HUVEC may be able to as-
semble the complete alternative complement pathway. Absence of Clq and C4bp1920
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FIGURE 2 .
￿
Expression of factor H by HUVEC : biosynthetic
labeling and Western blot analyses . (A)HUVEC were labeled with
[31SIcysteine for 12 h at confluence in the presence or absence of
IFN-y (100 IU/ml), and the supernatant was immunoadsorbed
with polyclonal anti-factorH antibodies . Specifically immunoad-
sorbed material was analyzed by SDS-PAGE under nonreducing
and reducing conditions as described in Materials and Methods .
(Lane a) ControlHUVEC, nonreducing conditions; (lane b), con-
trol HUVEC, reducing conditions ; (lane c), IFN-y-stimulated
HUVEC, nonreducing conditions ; (lane d) IFN-y-stimulated
HUVEC, reducing conditions . (B) HUVEC were maintained at
confluence in the presence or absence of IFN-y (100 IU/ml) for
3 d . The culture supernatants (100 pl) were then analyzed for the
presence of factor H by Western blotting using polyclonal
anti-factorH antibodies as described in Materials and Methods .
(Lane a) Medium only ; (lane b) controlHUVEC ; (lane c) IFN-y-
stimulated HUVEC . The gels were run under nonreducing con-
ditions .
mRNA may indicate general lack, or a low level, of synthesis of classical pathway
components and regulators.
Expression of complement components and modulation of this expression by IFN-
y is a further characteristic common to both endothelial cells and cells of mono-
cyte/macrophage lineage . The apparently high quantity of factor H mRNA rela-
tive to factor B mRNA in stimulated or unstimulated HUVEC may suggest that
complement secretion by these cells is principally protective . High levels of factor
H, together with DAF (4), may influence resistance of endothelial cells to comple-
ment attack or may reduce immune complex deposition on blood vessel was . Com-
plement components secreted byHUVEC may participate in local Cab deposition
on material destined for uptake by phagocytes, or maybe involved in C3 deposition
on endothelial cells themselves . Similar phenomena of covalent C3b deposition on
macrophage and monocytes have been described, and may be involved in cell-cell
FIGURE 3 .
￿
Expression of complement
factor I and factor B by HUVEC :
Northern blot analyses. Total RNA was
run under denaturing conditions and
blotted onto nitrocellulose . (A) The filter
was probed using the factor I-specific
cDNA probe. (a) totalRNA (20 jig) from
control HUVEC ; (b) total RNA (20 I+g)
from IFN-y-stimulated HUVEC . (B)The
filter was probed using a factor B-specific
cDNA probe . (a) total RNA (20 pg) from
IFN-y-stimulated HUVEC (100 IU/ml,
3 d) ; (b) total RNA (20 pg) from control
HUVEC ; (c) total RNA (4 pg) from
human liver.RIPOCHE ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
1921
interaction processes or in antigen processing (15). Cab, ifdeposited on endothelial
cells, would be rapidly converted to iC3b by the action offactors H and I, and would
serve as a local ligand for interaction ofendothelia with cells bearing CR3 or p150,95.
Recent work on inflammatory cell recruitment in vivo indicates a key role for CR3
at the stage of adhesion to endothelium (16). CR3 also plays a role in T cell-depen-
dent recruitment of myelomonocytic cells (Rosen, H., G. Milon, and S. Gordon,
unpublished results) . T cell-derived IFN-y may induce an appropriate ligand by
its effect on complement component secretion by endothelial cells and therefore may
have a role in adhesion of myelomonocytic cells.
Summary
Human umbilical vein endothelial cells grown in vitro under standard conditions
contain a high level of mRNA specific for the complement regulatory factors H
and I. An additional 1.8-kb mRNA encoding a truncated form of factor H is also
present. IFN-y stimulation of the cells causes a 6-7-fold increase in both factor H
mRNA species, and a >10-fold increase in factor I mRNA. IL-1 and LPS slightly
suppressed factor H mRNA, while TNF had no effect. mRNA for factor B is also
detectable in IFN-y-stimulated cells, but messengers for Clq, C4bp, and CR3 R chain
were not found. Secretion of factor H protein was also stimulated by IFN-y . The
presence of mRNA for factors H, B, and I, together with C3 secretion, demon-
strated by others, suggests that endothelial cells can assemble the complete alterna-
tive complement pathway. Endothelial cell complement may be involved in
leukocyte-endothelium interactions mediated by leukocyte C3 receptors.
We thank Professor M. R. Daha for discussion of results before publication, and Drs. P.
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